Loss of PEDF: A Novel Mechanism of Antihormone Resistance in Breast Cancer
Technical Report,01 Aug 2012,31 Jul 2015
University of Kansas Medical Center Kansas City United States
Pagination or Media Count:
Resistance to endocrine therapy such as tamoxifen or aromatase inhibitors is a major clinical obstacle to the effective treatment and cure of women with estrogen receptor ER-positive breast cancer. It is estimated that 40 of breast cancer patients will develop endocrine-resistant disease following long-term treatment. The possibility of identifying new targets for therapy in resistant disease, or patients, who may benefit from additional treatment with existing therapies, provides a strong impetus to identify markers and mediators of therapeutic resistance. Our laboratory has identified a novel protein called pigment epithelium derived factor PEDF that appears to be suppressedsilenced in endocrine resistant breast cancer.